The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes
- Eric S. Kilpatrick, MD, FRCPATH1,
- Alan S. Rigby, MSC2 and
- Stephen L. Atkin, PHD, FRCP3
- 1Department of Clinical Biochemistry, Hull Royal Infirmary, Hull, U.K.
- 2Academic Department of Cardiology, University of Hull, Hull, U.K.
- 3Department of Diabetes, Hull York Medical School, Hull, U.K.
- Address correspondence and reprint requests to Dr. Eric S. Kilpatrick, Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ. E-mail: eric.kilpatrick{at}hey.nhs.uk
Abstract
OBJECTIVE—It is not known whether glycemic instability may confer a risk of microvascular complications that is in addition to that predicted by the mean blood glucose (MBG) value alone. This study has analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess the effect of glucose variability on the risk of retinopathy and nephropathy in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS—Pre- and postprandial seven-point glucose profiles were collected quarterly during the DCCT in 1,441 individuals. The mean area under the curve glucose and the SD of glucose variability within 24 h and between visits were compared with the risk of retinopathy and nephropathy, having adjusted for age, sex, disease duration, treatment group, prevention cohort, and phase of treatment.
RESULTS—Multivariate Cox regression showed that within-day and between-day variability in blood glucose around a patient’s mean value has no influence on the development or progression of either retinopathy (P = 0.18 and P = 0.72, respectively) or nephropathy (P = 0.32 and P = 0.57). Neither preprandial (P = 0.18) nor postprandial (P = 0.31) glucose concentrations preferentially contribute to the probability of retinopathy.
CONCLUSIONS—This study has shown that blood glucose variability does not appear to be an additional factor in the development of microvascular complications. Also, pre- and postprandial glucose values are equally predictive of the small-vessel complications of type 1 diabetes.
- AER, albumin excretion rate
- AUC, area under the curve
- DCCT, Diabetes Control and Complications Trial
- MBG, mean blood glucose
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
See accompanying editorial, p. 1707.
-
- Accepted April 9, 2006.
- Received February 4, 2006.
- DIABETES CARE
